onasemnogene abeparvovec

Trials studying onasemnogene abeparvovec

• phase3Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trialsactive not recruitingn=20
• phase4ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)not yet recruitingn=36
• phase3Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copiescompletedn=2
• phase3Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2completedn=30
• phase3Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1completedn=33
• phase3Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1completedn=22
• phase1Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophyterminatedn=32
• phase3Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioiactive not recruitingn=85